Nebenwirkungen · Imfinzi
IMFINZI 50 mg/ml concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 30
HOS-141873 · Präparat HOS-098696
In first line metastatic NSCLC patients in the POSEIDON study, some differences in safety were reported between elderly (≥ 65 years) and younger patients. The safety data from patients 75 years of age or older are limited to a total of 74 patients. There was a higher frequency of serious adverse reactions and discontinuation rate of any study treatment due to adverse reactions in 35 patients aged 75 years of age or older treated with IMFINZI in combination with tremelimumab and platinum-based chemotherapy (45.7% and 28.6%, respectively) relative to 39 patients aged 75 years of age or older who received platinum-based chemotherapy only (35.9% and 20.5%, respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-18T16:10:00Z · SHA-256 2aea150cfee5fbe605596424a5c30efdb4cdb269005b61f75a72ebb78beb905f · Passage 53174a30525419fbac994889c772819d204d121b098e9d9af0f816f080ce040a · Zeichen 58798–59473 im Abschnitt